NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Forecast & News

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.03. View TRACON Pharmaceuticals' Earnings History.

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for TRACON Pharmaceuticals.

3 equities research analysts have issued 1 year target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $7.00 to $18.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 215.7% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.

News headlines about TCON stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for TRACON Pharmaceuticals.

TRACON Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 54,800 shares, an increase of 218.6% from the December 15th total of 17,200 shares. Based on an average daily volume of 232,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.9% of the company's shares are short sold. View TRACON Pharmaceuticals' Current Options Chain.

Some companies that are related to TRACON Pharmaceuticals include Vical (VICL), Neon Therapeutics (NTGN), Entera Bio (ENTX), Outlook Therapeutics (OTLK), aTyr Pharma (LIFE), Genetic Technologies (GENE), Vaxart (VXRT), Titan Pharmaceuticals (TTNP), Aevi Genomic Medicine (GNMX), TrovaGene (TROV), CytRx (CYTR), Enzon Pharmaceuticals (ENZN), AIM ImmunoTech (AIM), Seneca Biopharma (SNCA) and Vitro Diagnostics (VODG).

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include Verastem (VSTM), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), MEI Pharma (MEIP), Melinta Therapeutics (MLNT), Novavax (NVAX) and Opko Health (OPK).

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCON stock can currently be purchased for approximately $3.96.

TRACON Pharmaceuticals has a market capitalization of $12.43 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($13.00) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals.

The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/.

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]